This review highlights the establishment of ACE inhibitors as safe and effective first-line therapies for hypertension with pleiotropic benefits including renal and myocardial protection.
Supports ACE inhibitors as first-line hypertension therapy with pleiotropic benefits; leaves open comparative effectiveness versus contemporary agents in current populations.
Introduction of the first angiotensin-converting enzyme (ACE) inhibitor, captopril, in 1981 marked a major advance in the treatment of essential hypertension. This article reviews the 12 years of clinical experience during which it and other ACE inhibitors have become recognized as first-line agents for treating hypertension. The benefits of ACE inhibition in diabetic patients are being defined. In recent years, beneficial effects on glucose handling, leftventricular mass, quality of life, renal function, and myocardial protection have become recognized. For these reasons, and because of their excellent safety profile, ACE inhibitors are now widely used for the treatment of hypertensive patients. (Arch Intern Med. 1994;154:513-523)
No takes yet. Share an insight, caveat, or question.
B. J. Materson (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: